Risk Minimisation Materials

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV-1

This brochure contains important advice on the management of potential renal and bone effects of tenofovir disoproxil in HIV-1 infected children and adolescents aged 2 to <18 years, and the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals